Related Experiment Video
Updated: Jun 20, 2025

09:31
In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses
Published on: March 30, 2015
8.9K
[SMALL RENAL CELL CARCINOMA METASTASIS TO THE IPSILATERAL PERIRENAL FAT SYNCHRONOUSLY: A CASE REPORT]
Takanori Kinjo1, Haruka Izumi1, Tomohiro Kanaki1
1The Department of Urology, Ikeda Municipal Hospital.
Summary
This case report details the first instance of synchronous metastasis of small renal cell carcinoma to the ipsilateral perirenal fat. Treatment with pembrolizumab plus axitinib showed efficacy in managing pleural metastases.
Area of Science:
- Oncology
- Urology
Context:
- Small renal cell carcinoma (RCC) with metastases is uncommon.
- Synchronous metastasis to the ipsilateral perirenal fat in RCC is exceptionally rare, with this being the first reported case.
- The patient presented with early gastric carcinoma, incidentally found to have a right renal tumor and ipsilateral perirenal fat nodules.
Purpose:
- To report the first case of synchronous metastasis of small renal cell carcinoma to the ipsilateral perirenal fat.
- To describe the diagnostic and treatment course, including response to immunotherapy.
- To highlight the management of metastatic clear cell renal cell carcinoma.
Summary:
- A 70-year-old man with early gastric carcinoma was diagnosed with a 3 cm clear cell renal cell carcinoma (ccRCC) with synchronous metastasis to the ipsilateral perirenal fat (cT1aN0M1).
- Following laparoscopic radical nephrectomy, the patient developed multiple pleural metastases 11 months post-surgery.
- Treatment with pembrolizumab plus axitinib led to the disappearance of pleural metastases, although immunotherapy-related adverse events (diarrhea, hoarseness) necessitated treatment discontinuation. The patient remains recurrence-free at 36 months post-surgery.
Impact:
- This case expands the understanding of rare metastatic patterns in small renal cell carcinoma.
- It underscores the potential efficacy of combination immunotherapy (pembrolizumab plus axitinib) in managing metastatic ccRCC.
- The report highlights the importance of vigilant follow-up and management of immune-related adverse events in advanced RCC treatment.

